The study was presented at the Society of Interventional Radiology's 2018 Annual Scientific Meeting. The treatment was determined safe and feasible in the initial pilot phase.
‘New treatment of freezing hunger-signaling nerves is found to be safe and feasible for losing weight.’
"We developed this treatment for patients with mild-to-moderate obesity
to reduce the attrition that is common with weight-loss efforts," said David Prologo, M.D., FSIR, ABOM-D, an interventional radiologist from Emory University School of Medicine, and lead author of the study. "We are trying to help people succeed with their own attempts to lose weight
During the procedure, an interventional radiologist inserts a needle through the patient's back and, guided by live images from a CT scan, uses argon gas to freeze the nerve, known as the posterior vagal trunk. This nerve, located at the base of the esophagus, is one of several mechanisms that tells the brain that the stomach is empty.
In the study, 10 subjects with a body mass index (BMI)
between 30 and 37 underwent the procedure and were followed for 90 days. All subjects reported decreased appetite and the overall average weight loss was 3.6 percent of initial body weight and an average decline of nearly 14 percent of the excess BMI. No procedure-related complications were reported, and there were no adverse events during the follow up.
"Medical literature shows the vast majority of weight-loss programs fail, especially when people attempt to reduce their food intake," said Prologo.
"When our stomachs are empty, the body senses this and switches to food-seeking survival mode. We're not trying to eliminate this biological response, only reduce the strength of this signal to the brain to provide a new, sustainable solution to the difficult problem of treating mild obesity."
Following the success of this preliminary safety and feasibility study, more patients are being recruited for a larger clinical trial of the procedure to test the efficacy and durability of the procedure.
In presenting the study, the authors note several limitations, including the small sample size and the interim nature of the results.
The study was funded by HealthTronics, a medical technology company that manufactures the ablation probes used for the treatment.